Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Pegfilgrastim Revenues Set To Slide Again In 2022 Amid Challenging Market

Executive Summary

Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.

You may also be interested in...

Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program

Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.

Coherus Identifies Stealing Amgen’s Crown As Pegfilgrastim Market Leader

With its Udenyca pegfilgrastim biosimilar sales plunging in 2021 amid pricing and volume pressures, Coherus is looking to balance price and share trade-offs in 2022 before the intended launch of its proposed on-body injector device next year – in turn aiming to become the eventual pegfilgrastim market leader.

Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key

During the company’s landmark first annual analyst day, Coherus BioSciences management spoke at length about its ambitions for Coherus to generate north of $2bn in revenues by 2026, with much riding on how it fares in the impending biosimilar Humira market.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts